Safety and Efficacy of Propofol Sedation in Outpatient Colonoscopy: Findings from a Cross-Sectional Study

Abstract

Introduction: Colonoscopy is crucial for early detection of colorectal cancer, and sedation is essential for patient comfort. Propofol, a fast-acting intravenous anesthetic, is gaining popularity for outpatient colonoscopy due to its safety, rapid onset, and recovery times. This study evaluates the safety and efficacy of propofol sedation in outpatient colonoscopy at North East Medical College, Sylhet, addressing patient demographics, sedation parameters, adverse events, and recovery. Objectives: To assess the safety, efficacy, and patient satisfaction of propofol sedation in outpatient colonoscopy, analyzing dosage, adverse events, and recovery. Methods and Materials: This cross-sectional study was conducted at North East Medical College, Sylhet, from June 2022 to May 2023. A total of 102 participants undergoing outpatient colonoscopy with propofol sedation were included. Data were collected using a structured sheet, covering demographics, indications, sedation dosage, adverse events, recovery time, and patient satisfaction. SPSS version 21.0.1 was used for analysis, with descriptive statistics employed to summarize the results. Ethical approval and informed consent were obtained. Result: The study included 102 participants with a mean age of 45.2 years. Of these, 58.8% were male, and 39.2% were professionals. The most common indication for colonoscopy was screening (34.3%). The majority received 101–200 mg of propofol (49%). Adverse events occurred in 32.4%, with hypotension (14.7%) being the most common. Recovery time was under 30 minutes for 73.5%, and 58.8% of patients were very satisfied with the sedation. Conclusion: This study confirms that propofol sedation is safe, effective, and well-tolerated in outpatient colonoscopy, with minimal adverse events, rapid recovery, and high patient satisfaction, supporting its routine use in clinical practice.